Loading stock data…
OCS
$10.98+0.27 (+2.52%)
After Hours$10.80-0.18 (-1.64%)· Last close Jun 9
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Oculis Holding AG in the Healthcare sector is trading at $10.98. Wall Street consensus targets $37.95 (11 analysts), implying a +245.6% move over the next 12 months. The stock is currently near its 52-week low of $10.52, remaining 52.3% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 18 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +245.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 18) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$10.98
Potential Downside
0%
Whystock Fair Value$10.98
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Mean target$37.95+245.6%
Range$22.68 – $51.98
Fundamentals
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dex...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-48.10%
Volume
Today's trading volume
1.01M
Recent News
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles
Oculis advances late-stage topical therapies for diabetic and neuro-ophthalmic eye diseases in the clinical-stage biotech sector.
Oculis Shelves FDA Filing After Phase 3 DME Trials Miss Key Vision Goals
Oculis (NASDAQ:OCS) said its two Phase 3 DIAMOND trials of OCS-01 in diabetic macular edema did not meet their primary endpoints, and the company does not currently plan to pursue a U.S. Food and Drug Administration filing for the drug candidate in that indication. Chief Executive Officer Riad Sher
OCS Stock Drops Over 23% — Eye Drop Trial For Diabetic Vision Loss Misses Target
Oculis said it will not pursue US Food and Drug Administration (FDA) filing for OCS-01 in diabetic macular edema following disappointing late-stage trial results.
Oculis Holding AG Phase 3 Trial of Potential Eye Drops for Diabetic Patients Fails to Primary Endpoint
Oculis Holding AG (OCS) said Thursday its Phase 3 DIAMOND-1 and DIAMOND-2 trials evaluating OCS-01 e
Etsy upgraded, ZoomInfo downgraded: Wall Street's top analyst calls
Etsy upgraded, ZoomInfo downgraded: Wall Street's top analyst calls